ProCE Banner Activity

Application and Implications of High-Impact Data From the European Hematology Association Virtual Congress 2021

Slideset Download
Conference Coverage
Download this summary slideset covering high-impact data for key studies in blood cancers and nonmalignant blood disorders as presented at the virtual 2021 EHA annual meeting.

Released: July 16, 2021

Expiration: July 15, 2022

No longer available for credit.

Share

Faculty

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci

Academic Director, Centre for Clinical Haematology
Chair, UK NCRI AML Working Party
University Hospitals Birmingham
Director, Blood and Marrow Transplant Unit
Professor of Haemato-oncology
University Hospitals Birmingham NHS Foundation Trust, UK
Birmingham, United Kingdom

María-Victoria Mateos

María-Victoria Mateos, MD, PhD

Associate Professor
Department of Hematology
University of Salamanca
Director, Myeloma Unit
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

Ali T. Taher

Ali T. Taher, MD, PhD, FRCP

Professor of Medicine, Hematology and Oncology
Division of Hematology and Oncology
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Bristol Myers Squibb

Jazz Pharmaceuticals

Faculty Disclosure

Primary Author

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci

Academic Director, Centre for Clinical Haematology
Chair, UK NCRI AML Working Party
University Hospitals Birmingham
Director, Blood and Marrow Transplant Unit
Professor of Haemato-oncology
University Hospitals Birmingham NHS Foundation Trust, UK
Birmingham, United Kingdom

Prof. Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci, has disclosed that he has received consulting/advisory fees from AbbVie, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Eurocept, Janssen, Jazz, Kite, Novartis, Pfizer, and Roche; fees for non-CME/CE services from AbbVie, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Eurocept, Janssen, Novartis, Pfizer, and Roche; and funds for research support from Jazz and Kite.

María-Victoria Mateos, MD, PhD

Associate Professor
Department of Hematology
University of Salamanca
Director, Myeloma Unit
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

María-Victoria Mateos, MD, PhD, has disclosed that she has received consulting/advisory fees from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche/Genentech, and Takeda and funds for non-CME/CE services from AbbVie/Genentech, Adaptive, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, and Takeda.

Ali T. Taher, MD, PhD, FRCP

Professor of Medicine, Hematology and Oncology
Division of Hematology and Oncology
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon

Ali T. Taher, MD, PhD, has disclosed that he has received consulting fees from Agios, Bristol-Myers Squibb/Celgene, Ionis, Novartis, and Vifor; funds for research support from Bristol-Myers Squibb/Celgene, Ionis, Novartis, and Vifor.